Eunice Wang's guest appearances

Eunice Wang

Hematologic Oncology Update

Research To Practice | Oncology Videos

AAMDSIF Podcasts for Patients

Nina Shah

Gilles A Salles

Daniel Pollyea

Sonali M Smith

Rafael Fonseca

Jeff Sharman

Jennifer R Brown

Ola Landgren

Radhakrishnan Ramchandren

Mark Levis

Nathan H Fowler

Gail J Roboz

Edward A Stadtmauer

Irene M Ghobrial

Laurie H Sehn

OwlTail

Dr. Eunice Wang explains the origin and treatment of secondary MDS. Dr. Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Center.

AAMDSIF Podcast Episode 49: Dr. Eunice Wang discusses Secondary MDS

Acute Leukemias Update, Issue 1, 2020 — Part 2: Our interview with Dr Wang highlights the following topics as well as cases from her practice:  Case: A woman in her early 60s with previously treated metastatic triple-negative breast cancer is diagnosed with AML with a FLT3-ITD mutation (00:00) Molecular profiling in the diagnosis and treatment of AML (01:54) Activity and tolerability of midostaurin in combination with standard 7 + 3 chemotherapy for newly diagnosed AML with a FLT3 mutation (05:14) CPX-351 for secondary AML (07:16) Incidence and characterization of FLT3 mutations in AML; efficacy of midostaurin and gilteritinib (10:45) Clinical experience with and tolerability of gilteritinib (16:12) Activity of midostaurin in newly diagnosed AML with a FLT3 mutation (20:54) Ongoing Phase III trials of crenolanib, gilteritinib and quizartinib as first-line therapy for AML with a FLT3 mutation (24:17) Significance of allelic ratio in AML with a FLT3-ITD mutation (26:50) Therapeutic options for patients with relapsed/refractory AML and metastatic triple-negative breast cancer (31:01) Activity and safety of immune checkpoint inhibitors in patients with AML (32:58) Biologic rationale for and activity of venetoclax in combination with a hypomethylating agent for patients with AML (35:06) Case: A man in his early 40s with relapsed/refractory AML with an IDH2 mutation receives enasidenib (36:32) Similarities and differences between enasidenib and ivosidenib; recognition and management of treatment-associated differentiation syndrome (39:22) Integration of the FDA-approved IDH inhibitors enasidenib and ivosidenib into clinical practice (44:15) Approach to therapy for older patients with AML with FLT3 or IDH1/2 mutations (46:56) Integration of venetoclax in combination with a hypomethylating agent into community practice (51:23) Use of gemtuzumab ozogamicin for patients with low- to intermediate-risk AML with no adverse cytogenetics (55:33) Activity and unique side-effect profile of the hedgehog inhibitor glasdegib for AML (58:17) Results of the Phase III QUAZAR AML-001 trial: Overall survival benefit with CC-486 as maintenance therapy for newly diagnosed AML in first remission (1:00:34) Mechanism of action and activity of the first-in-class small molecule APR-246 in combination with azacitidine for patients with AML or myelodysplastic syndromes with TP53 mutations (1:04:19) Mechanisms of action and activity of blinatumomab and the antibody-drug conjugate inotuzumab ozogamicin in patients with relapsed/refractory ALL (1:06:44) Tolerability and safety of blinatumomab and inotuzumab ozogamicin (1:09:51)  CME information and select publications

<p>Acute Leukemias Update, Issue 1, 2020 — Part 2: Our interview with Dr Wang highlights the following topics as well as cases from her practice:</p> <ul> <li>Case: A woman in her early 60s with previously treated metastatic triple-negative breast cancer is diagnosed with AML with a FLT3-ITD mutation (00:00)</li> <li>Molecular profiling in the diagnosis and treatment of AML (01:54)</li> <li>Activity and tolerability of midostaurin in combination with standard 7 + 3 chemotherapy for newly diagnosed AML with a FLT3 mutation (05:14)</li> <li>CPX-351 for secondary AML (07:16)</li> <li>Incidence and characterization of FLT3 mutations in AML; efficacy of midostaurin and gilteritinib (10:45)</li> <li>Clinical experience with and tolerability of gilteritinib (16:12)</li> <li>Activity of midostaurin in newly diagnosed AML with a FLT3 mutation (20:54)</li> <li>Ongoing Phase III trials of crenolanib, gilteritinib and quizartinib as first-line therapy for AML with a FLT3 mutation (24:17)</li> <li>Significance of allelic ratio in AML with a FLT3-ITD mutation (26:50)</li> <li>Therapeutic options for patients with relapsed/refractory AML and metastatic triple-negative breast cancer (31:01)</li> <li>Activity and safety of immune checkpoint inhibitors in patients with AML (32:58)</li> <li>Biologic rationale for and activity of venetoclax in combination with a hypomethylating agent for patients with AML (35:06)</li> <li>Case: A man in his early 40s with relapsed/refractory AML with an IDH2 mutation receives enasidenib (36:32)</li> <li>Similarities and differences between enasidenib and ivosidenib; recognition and management of treatment-associated differentiation syndrome (39:22)</li> <li>Integration of the FDA-approved IDH inhibitors enasidenib and ivosidenib into clinical practice (44:15)</li> <li>Approach to therapy for older patients with AML with FLT3 or IDH1/2 mutations (46:56)</li> <li>Integration of venetoclax in combination with a hypomethylating agent into community practice (51:23)</li> <li>Use of gemtuzumab ozogamicin for patients with low- to intermediate-risk AML with no adverse cytogenetics (55:33)</li> <li>Activity and unique side-effect profile of the hedgehog inhibitor glasdegib for AML (58:17)</li> <li>Results of the Phase III QUAZAR AML-001 trial: Overall survival benefit with CC-486 as maintenance therapy for newly diagnosed AML in first remission (1:00:34)</li> <li>Mechanism of action and activity of the first-in-class small molecule APR-246 in combination with azacitidine for patients with AML or myelodysplastic syndromes with TP53 mutations (1:04:19)</li> <li>Mechanisms of action and activity of blinatumomab and the antibody-drug conjugate inotuzumab ozogamicin in patients with relapsed/refractory ALL (1:06:44)</li> <li>Tolerability and safety of blinatumomab and inotuzumab ozogamicin (1:09:51)</li> </ul> <p><a href="http://m.researchtopractice.com/AcuteLeukemiasUpdate120/Video" rel="nofollow" target="_blank">CME information and select publications</a></p>

Acute Leukemias | Eunice Wang, MD

Acute Leukemias Update - Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Eunice Wang, MD conducted by Neil Love, MD. Produced by Research To Practice.

Acute Leukemias Update 1 2020 | Interview with Eunice Wang, MD